HirvaMansuraliMamdaniMD

Thoracic Cancer

Medical Oncology, Karmanos Cancer Institute. Assistant Professor of Medicine, Wayne State University

Dr. Mamdani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Hirva Mamdani is a medical oncologist specializing in treatment of thoracic malignancies, including lung cancer, mesothelioma, and esophageal cancer. She is affiliated with Karmanos Cancer Institute - an NCI designated comprehensive cancer center. Dr. Mamdani received her medical degree from M.P. Shah Medical College in India. She completed her residency from Wayne State University, Detroit MI and fellowship training from Indiana University, Indianapolis IN. Dr. Mamdani is involved in a large number of national and global clinical trials evaluating novel therapeutic agents for the treatment of thoracic cancers. Her areas of research interest include immunotherapy and DNA repair pathways.

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2014 - 2017
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2011 - 2014
M.P. Shah Medical CollegeClass of 2009

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer Start of enrollment: 2022 Apr 15
Terminated
Phase 2
Roles: Principal Investigator, Contact
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Start of enrollment: 2020 Jun 10
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. Start of enrollment: 2022 Aug 26
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer Start of enrollment: 2023 Sep 26
Recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator, Contact
A Study of SGN-EGFRd2 in Advanced Solid Tumors Start of enrollment: 2023 Nov 14
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

PubMed

Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort.
J Nicholas Bodor, Joanne Xiu, Vinicius Ernani, Supreet Kaur, Hirva Mamdani
Clinical Lung Cancer. 2024-11-01
Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy.
Elisabeth Heath, Gregory Dyson, Jennifer R Ribeiro, Joanne Xiu, Kelsey Poorman
Cancer Research Communications. 2024-10-01
2 citations
Racial and socioeconomic disparities in survival among patients with metastatic non-small cell lung cancer.
Dipesh Uprety, Randell Seaton, Tarik Hadid, Hirva Mamdani, Ammar Sukari
Journal of the National Cancer Institute. 2024-10-01

Lectures

Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cance...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consorti...
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Join now to see all

Karmanos Cancer Institute Recognizes Lung Cancer Awareness Month, Encourages ScreeningsNovember 4th, 2024
Early Detection Is Key for This Common Form of CancerNovember 21st, 2022
Karmanos Cancer Institute Partners with Nation's Top Cancer Organizations to Endorse Initiative to Increase Lung Cancer Screening in the United StatesNovember 1st, 2022
Join now to see all